• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Consensus statement on human immunodeficiency virus pre-exposure prophylaxis in China.

作者信息

Xu Jun-Jie, Huang Xiao-Jie, Liu Xin-Chao, Wang Li-Ming, Chen Yao-Kai, Wang Hui, Zhang Fu-Jie, Wu Hao, Li Tai-Sheng, Han Meng-Jie, Zhao Fang, Ding Hai-Bo, Duan Jun-Yi, Sheng Gen-Shen, Shang Hong

机构信息

National Health Commission (NHC) Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China.

Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, Liaoning 110001, China.

出版信息

Chin Med J (Engl). 2020 Dec 5;133(23):2840-2846. doi: 10.1097/CM9.0000000000001181.

DOI:10.1097/CM9.0000000000001181
PMID:33273333
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10631579/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbd9/10631579/cab40302bf8c/cm9-133-2840-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbd9/10631579/12762cbd1425/cm9-133-2840-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbd9/10631579/cab40302bf8c/cm9-133-2840-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbd9/10631579/12762cbd1425/cm9-133-2840-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbd9/10631579/cab40302bf8c/cm9-133-2840-g002.jpg

相似文献

1
Consensus statement on human immunodeficiency virus pre-exposure prophylaxis in China.中国人类免疫缺陷病毒暴露前预防共识声明
Chin Med J (Engl). 2020 Dec 5;133(23):2840-2846. doi: 10.1097/CM9.0000000000001181.
2
Preexposure Prophylaxis for the Prevention of HIV Infection: Recommendation Statement.暴露前预防艾滋病病毒感染：推荐声明。
Am Fam Physician. 2019 Nov 15;100(10):Online.
3
Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out.暴露前预防在人群层面上有作用吗？尚无定论。
Clin Infect Dis. 2020 Dec 15;71(12):3152-3153. doi: 10.1093/cid/ciz1236.
4
"Meds-in-Hand" Intervention to Reduce Critical Process Delays in Pediatric Human Immunodeficiency Virus Post-Exposure Prophylaxis."手头上的药物"干预措施以减少儿科人类免疫缺陷病毒暴露后预防中的关键流程延误。
J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):196-200. doi: 10.1093/jpids/piaa033.
5
Minimum dataset for monitoring national human immunodeficiency virus pre-exposure prophylaxis (HIV PrEP) programmes: a five-nation consensus, 2019.监测国家人类免疫缺陷病毒暴露前预防（HIV PrEP）项目的最小数据集：2019年五国共识
Euro Surveill. 2021 Jun;26(23). doi: 10.2807/1560-7917.ES.2021.26.23.2001595.
6
Pre-Exposure Prophylaxis as a Method for Prevention of Human Immunodeficiency Virus Infection.暴露前预防作为一种预防人类免疫缺陷病毒感染的方法。
Isr Med Assoc J. 2016 May;18(5):294-8.
7
Redefining Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis Failures.重新定义人类免疫缺陷病毒（HIV）暴露前预防失败
Clin Infect Dis. 2017 Oct 30;65(10):1768-1769. doi: 10.1093/cid/cix593.
8
Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).中国男男性行为人群中 HIV 暴露前预防多中心真实世界研究方案（CROPrEP）
BMC Infect Dis. 2019 Aug 15;19(1):721. doi: 10.1186/s12879-019-4355-y.
9
Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco.旧金山大型医疗体系中采用事件驱动型人类免疫缺陷病毒暴露前预防措施的早期采用者。
Clin Infect Dis. 2020 Dec 17;71(10):2710-2712. doi: 10.1093/cid/ciaa474.
10
Pre-exposure prophylaxis for human immunodeficiency virus: the past, present, and future.人类免疫缺陷病毒暴露前预防：过去、现在与未来
Infect Dis Clin North Am. 2014 Dec;28(4):563-83. doi: 10.1016/j.idc.2014.08.001. Epub 2014 Nov 20.

引用本文的文献

1
Preference for HIV Pre-exposure Prophylaxis Access Among Men who Have Sex With Men in China: A Discrete Choice Experiment.中国男男性行为者对艾滋病病毒暴露前预防药物获取的偏好：一项离散选择实验
Open Forum Infect Dis. 2025 Jan 9;12(1):ofae742. doi: 10.1093/ofid/ofae742. eCollection 2025 Jan.
2
Analysis of HIV drug prophylaxis services cascade in healthcare workers: a cross-sectional study in China.分析中国医护人员中 HIV 药物预防服务的传递情况：一项横断面研究。
BMC Infect Dis. 2024 Jan 2;24(1):4. doi: 10.1186/s12879-023-08873-x.
3
Multi-dimensional mismatch and barriers for promoting PrEP among men who have sex with men in China: a cross sectional survey from the Demand-side.

本文引用的文献

1
Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.中国 HIV 感染患者中基于替诺福韦酯的抗逆转录病毒治疗的血脂谱和肾脏安全性。
Int J Infect Dis. 2019 Jun;83:64-71. doi: 10.1016/j.ijid.2019.03.034. Epub 2019 Apr 2.
2
Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.尽管对每日暴露前预防治疗高度依从，但仍获得对替诺福韦敏感、对恩曲他滨耐药的艾滋病毒：一例病例报告。
Lancet HIV. 2018 Nov 29. doi: 10.1016/S2352-3018(18)30288-1.
3
A systematic review of adherence to oral pre-exposure prophylaxis for HIV - how can we improve uptake and adherence?
中国男男性行为者中推广 PrEP 的多维不匹配和障碍：来自需求方的横断面调查。
AIDS Res Ther. 2023 Feb 13;20(1):11. doi: 10.1186/s12981-022-00497-6.
4
An integrated online-to-offline model for HIV post-exposure prophylaxis (O2O-PEP) scale-up among men who have sex with men (MSM): Protocol for developing a pilot randomized controlled trial.一项男男性行为者（MSM）人群中扩大艾滋病毒暴露后预防（O2O-PEP）的整合线上到线下模型：一项开展试点随机对照试验的方案。
Front Public Health. 2022 Nov 16;10:1026137. doi: 10.3389/fpubh.2022.1026137. eCollection 2022.
5
Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial.中国男男性行为者中 HIV 暴露前预防用药与 HIV 发病率的关联：一项非随机对照试验。
JAMA Netw Open. 2022 Feb 1;5(2):e2148782. doi: 10.1001/jamanetworkopen.2021.48782.
系统评价口服暴露前预防 HIV 的依从性——我们如何提高使用率和依从性？
BMC Infect Dis. 2018 Nov 16;18(1):581. doi: 10.1186/s12879-018-3463-4.
4
Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis.基于替诺福韦酯口服暴露前预防对男男性行为者的疗效和安全性：一项系统评价和荟萃分析。
Front Pharmacol. 2018 Sep 4;9:799. doi: 10.3389/fphar.2018.00799. eCollection 2018.
5
Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.暴露前预防的血清转化：一份通过分段头发分析来确定定时依从性的案例报告。
AIDS. 2018 Jun 1;32(9):F1-F4. doi: 10.1097/QAD.0000000000001825.
6
Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.替诺福韦艾拉酚胺及其活性代谢产物在黏膜组织中的单剂量药代动力学。
J Antimicrob Chemother. 2017 Jun 1;72(6):1731-1740. doi: 10.1093/jac/dkx064.
7
[A cohort study of HIV incidence among injecting drug users in Dehong Prefecture, Yunnan Province].[云南省德宏州注射吸毒人群艾滋病病毒感染率队列研究]
Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Nov 6;50(11):966-970. doi: 10.3760/cma.j.issn.0253-9624.2016.11.009.
8
Pharmacology supports on-demand PrEP.药理学支持按需服用暴露前预防药物。
Lancet HIV. 2016 Sep;3(9):e405-e406. doi: 10.1016/S2352-3018(16)30114-X.
9
HIV incidence and associated risk factors in men who have sex with men in Mainland China: an updated systematic review and meta-analysis.中国大陆男男性行为者中的艾滋病毒发病率及相关危险因素：一项更新的系统评价和荟萃分析。
Sex Health. 2016 May 26. doi: 10.1071/SH16001.
10
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.针对所有人群的口服HIV暴露前预防的有效性和安全性。
AIDS. 2016 Jul 31;30(12):1973-83. doi: 10.1097/QAD.0000000000001145.